Mr. Tepper is co-head of FBC’s Hi-Tech Department and a partner in the firm’s Corporate Department. Mr. Tepper has a diverse corporate practice, encompassing mergers and acquisitions, securities law, corporate finance, and general corporate matters. He has represented public and private acquirers and target companies, and private equity firms and investment banks in a variety of domestic and cross-border mergers and acquisitions transactions, divestitures, joint ventures, restructurings, and other corporate matters.
In addition, Mr. Tepper provides day-to-day counseling to the firm's technology clients with a particular focus on life science and medical service providers, playing a key role in advising clients in all stages of their development, from start-up through to public offering.
Mr. Tepper has been involved in the establishment and representation of private investment and private equity funds. In addition, Mr. Tepper has an active practice representing international clients in their business activities in Israel.
Mr. Tepper joined the firm in 1999 and during the years 2001 and 2005, Mr. Tepper was an associate in the New York office of Skadden, Arps, Slate, Meagher & Flom LLP, where he was involved in a number of significant merger and acquisition transactions.
Mergers & Acquisitions
Life Sciences & Health Care
New York, 2002
Northwestern University – Kellogg School of Management (International Executive MBA), 2009
Tel Aviv University (LL.B.), 1997
FBC, in collaboration with US firm Morgan, Lewis & Bockius, represented Perrigo Company in the sale of its active pharmaceutical ingredients business headquartered in Israel for a purchase price of US$110 million. The transaction included the sale of all of the shar...Raz Tepper & Sharon Klein-Manbar & Anat Shavit & Shay Teken & Talia Shekel & Idan Lange & Moran Friedman & Hilla Sachs & Tal Wiesengrun & Boaz Tavor | Aug 2017
FBC represented Kamada Ltd., listed on NASDAQ and the Tel Aviv Stock Exchange, in its US$15 million follow-on underwritten public offering of its ordinary shares. Kamada also granted the underwriters a 30-day option to purchase additional ordinary shares, for aggregate ...Raz Tepper & Sharon Rosen & Anat Shavit & Nadav Oberman & Carolyn Zeimer-Vigodny | Aug 2017
FBC represented the SKY and Kedma Capital private equity funds in a transaction for the purchase of 70% of the shares of S.AL Holdings Ltd., in consideration of approximately NIS 136.5M. The consummation of the transaction is subject to the approval of the Israel Antitr...Raz Tepper & Sharon Klein-Manbar & Michael Zellermayer & Ziv Schwartz & Roni Bar-On & Nevo Ben-Shitrit | Jul 2017
FBC represented OrbiMed in its $5,325,000 investment in MobileODT Ltd. as part of a Series B Round of approximately $6,825,000 investment, in addition to conversion of SAFEs ("simple agreement for future equity") in the amount of $3,905,223. The transaction included ...Raz Tepper & Shmulik Fried & Talia Shekel | Jul 2017
Click here to view the full update New Rules Published by the Israeli Innovation Authority In May 2017, the Israeli Innovation Authority (the successor of the Office of Chief Scientist), a division of the Israeli Ministry of Economy and Industry (the "Innovation A...Raz Tepper & Shmulik Fried | Jun 2017